Compare GENK & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GENK | IMRN |
|---|---|---|
| Founded | 2011 | 1994 |
| Country | United States | Australia |
| Employees | 2700 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 7.7M |
| IPO Year | 2023 | 2016 |
| Metric | GENK | IMRN |
|---|---|---|
| Price | $1.52 | $0.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 35.0K |
| Earning Date | 11-10-2026 | 08-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $208,380,000.00 | N/A |
| Revenue This Year | $2.05 | $16.39 |
| Revenue Next Year | $4.93 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.12 | N/A |
| 52 Week Low | $1.39 | $0.68 |
| 52 Week High | $3.12 | $2.18 |
| Indicator | GENK | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 35.48 |
| Support Level | $1.53 | $0.94 |
| Resistance Level | $2.25 | $1.00 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 14.41 | 15.45 |
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. The group operates its restaurants in California, Arizona, Hawaii, Nevada, Texas, New York, Oregon, North Carolina, Washington, New Jersey, Florida and South Korea.
Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.